Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Hyaluronidase

Drug class: Endoglycosidase

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Hyaluronidase used for?
The FDA-approved label (Amphadase, Amphastar Pharmaceuticals, Inc., February 1, 2024) says: “Amphadase ® is an endoglycosidase indicated as an adjuvant: • in subcutaneous fluid administration for achieving hydration • to increase absorption and dispersion of other injected drugs • in subcutaneous urography for improving resorption of radiopaque agents 1.1 Subcutaneous Fluid Administration Amphadase ® is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Hyaluronidase have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Hyaluronidase?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Hyaluronidase been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Hyaluronidase?
1 company lists prescription products of Hyaluronidase in the FDA NDC Directory, including Amphastar Pharmaceuticals, Inc..

What Hyaluronidase is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Amphadase ® is an endoglycosidase indicated as an adjuvant: • in subcutaneous fluid administration for achieving hydration • to increase absorption and dispersion of other injected drugs • in subcutaneous urography for improving resorption of radiopaque agents 1.1 Subcutaneous Fluid Administration Amphadase ® is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. …

— FDA label: Amphadase, Amphastar Pharmaceuticals, Inc., effective February 1, 2024. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Forms and how it is given

Dosage formsInjection
RouteSubcutaneous
Prescription products1 in the FDA NDC Directory
Brand namesAmphadase

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
BLA021665
AMPHADASE
Amphastar PharmOctober 26, 2004 5, latest August 28, 2024
2024: Labeling · 2015: Manufacturing (CMC) · 2012: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)238271, 542925
SPL set ID of the quoted label8396ea96-7cb5-4e26-87a4-90bca9c3c6dd
FDA labels (SPL)1
FDA applicationsBLA021665
Active ingredients (FDA)HYALURONIDASE

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Amphadase, Amphastar Pharmaceuticals, Inc., effective February 1, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers